MIGUEL JOSE
MARTIN JIMÉNEZ
Profesor emérito
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicacions en col·laboració amb investigadors/es de University of Texas MD Anderson Cancer Center (40)
2022
-
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Molecular Cancer Therapeutics, Vol. 21, Núm. 4, pp. 625-634
-
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
Clinical Cancer Research, Vol. 28, Núm. 7, pp. 1383-1390
-
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Clinical Cancer Research, Vol. 28, Núm. 9, pp. 1854-1862
-
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Journal for immunotherapy of cancer, Vol. 10, Núm. 2
-
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160
2021
-
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Outcomes in clinically relevant patient subgroups from the EMBRACA study: Talazoparib vs physician's choice standard-of-care chemotherapy
JNCI Cancer Spectrum, Vol. 4, Núm. 1
-
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
Annals of Oncology, Vol. 31, Núm. 11, pp. 1526-1535
2019
2018
-
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
Annals of Oncology, Vol. 29, Núm. 3, pp. 669-680
-
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 1, pp. 115-126
-
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial
Annals of Oncology, Vol. 29, Núm. 9, pp. 1939-1947
-
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
New England Journal of Medicine, Vol. 379, Núm. 8, pp. 753-763
2016
-
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
European Journal of Cancer, Vol. 53, pp. 75-83
-
HER2 gene amplification testing by fluorescent in situ hybridization (FISH): Comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trials
Journal of Clinical Oncology, Vol. 34, Núm. 29, pp. 3518-3528
-
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
European Journal of Cancer, Vol. 56, pp. 85-92
-
Palbociclib and letrozole in advanced breast cancer
New England Journal of Medicine, Vol. 375, Núm. 20, pp. 1925-1936
2015
-
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial
Annals of Oncology, Vol. 26, Núm. 8, pp. 1722-1728
-
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer
European Journal of Cancer